North America Epigenetics Diagnostic Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
 예측 기간 |
2021 –2028 |
 시장 규모(기준 연도) |
USD 1,823.57 Million |
 시장 규모(예측 연도) |
USD 5,810.57 Million |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
>북미 후성유전학 진단 시장, 제품별( 시약 , 키트, 기기 및 소모품, 생물정보학 도구 및 효소), 기술(DNA 메틸화, 히스톤 메틸화, 크로마틴 구조, 히스톤 아세틸화, 대형 비코딩 RNA 및 마이크로RNA 변형), 치료 유형(히스톤 탈아세틸화효소(HDAC) 억제제, DNA 메틸전이효소(DNMT) 억제제 및 기타), 응용 분야( 종양학 , 심혈관 질환, 대사 질환, 면역학, 염증성 질환, 감염성 질환 및 기타), 최종 사용자(학술 및 연구 기관, 제약 및 생명 공학 회사, 계약 연구 기관(CRO) 및 기타), 유통 채널(직접 입찰 및 소매 판매), 국가(미국, 캐나다, 멕시코) 산업 동향 및 2028년까지의 예측.
시장 분석 및 통찰력: 북미 에피제네틱스 진단 시장
북미 에피제네틱스 진단 시장은 2021년부터 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년부터 2028년까지의 예측 기간 동안 16.0%의 CAGR로 성장하고 있으며 2020년의 1,823.57백만 달러에서 2028년까지 5,810.57백만 달러에 도달할 것으로 예상된다고 분석했습니다. 만성 질환의 높은 유병률과 기술 개발은 예측 기간 동안 시장 수요를 촉진하는 주요 동인이 될 가능성이 높습니다.
후생유전학 진단은 외부 환경에 의해 발생하는 유전학, 세포 및 물리적 특성 변화, 발달 생물학을 연구하는 것입니다. 이는 유전자와 유전자형의 변화에 영향을 받지 않고 유전자를 읽는 세포의 능력에 영향을 미칩니다. 후생유전학 변화는 유전자형이 아닌 유기체의 표현형의 변화로 이어지고, 기본 DNA 및 RNA 시퀀스는 변하지 않습니다. 후생유전학 변화는 역동적이고 환경에 따라 변화하기 때문에 발달에 필수적입니다.
생물체의 유전적 발현은 후성유전학의 영향을 받으며, 이로 인해 후성유전학은 분자생물학 및 발생유전학에서 가장 중요한 분야가 되었습니다. National Center Institute, National Institute of Health, International Human Epigenome Consortium과 같은 기관은 후성유전학 분야와 관련된 연구 및 개발 활동을 자금 지원하고 있습니다. 후성유전학은 또한 암, 대사 질환 등과 같은 다양한 만성 질환을 치료하는 데 사용됩니다.
북미 에피제네틱스 진단 시장 보고서는 시장 점유율, 새로운 개발, 국내 및 지역 시장 참여자의 영향에 대한 세부 정보를 제공하고, 새로운 수익 창출, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서 기회를 분석합니다. 분석 및 시장 시나리오를 이해하려면 분석가 브리핑을 위해 저희에게 연락하세요. 저희 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드릴 것입니다.
북미 에피제네틱스 진단 시장 범위 및 시장 규모
북미 에피제네틱스 진단 시장은 제품, 기술, 치료 유형, 응용 프로그램, 최종 사용자 및 유통 채널을 기반으로 하는 6가지 주요 세그먼트로 분류됩니다. 세그먼트 간의 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.
- 제품을 기준으로 북미 에피제네틱스 진단 시장은 시약, 키트, 기기 및 소모품, 생물정보학 도구, 효소로 세분화됩니다. 2021년에는 시약 부문이 시장을 지배할 것으로 예상되는데, 시약은 연구, 진단, 생명과학, 교육을 포함한 다양한 분야에서 사용되기 때문입니다.
- 기술에 따라 북미 에피제네틱스 진단 시장은 DNA 메틸화, 히스톤 메틸화, 크로마틴 구조, 히스톤 아세틸화, 대형 비코딩 RNA, 마이크로RNA 변형으로 세분화됩니다. 2021년에는 DNA 메틸화 기술이 다양한 에피제네틱스 진단에 사용되고 있기 때문에 DNA 메틸화 세그먼트가 시장을 지배할 것으로 예상됩니다.
- 치료 유형에 따라 북미 에피제네틱스 진단 시장은 히스톤 데아세틸라제(HDAC) 억제제, DNA 메틸트랜스퍼라제(DNMT) 억제제 등으로 세분화됩니다. 2021년에는 히스톤 데아세틸라제(HDAC) 억제제 세그먼트가 생물학적 과정에서 중요한 역할을 하고 유전자 발현을 조절하기 때문에 시장을 지배할 것으로 예상됩니다.
- 응용 프로그램을 기준으로 북미 에피제네틱스 진단 시장은 종양학, 심혈관 질환, 대사 질환, 면역학, 염증성 질환 등으로 세분화됩니다. 2021년에는 암 진단을 위한 에피제네틱스 사용이 증가함에 따라 종양학 부문이 시장을 지배할 것으로 예상됩니다.
- 최종 사용자를 기준으로 북미 에피제네틱스 진단 시장은 학술 및 연구 기관, 제약 및 생명공학 회사, 계약 연구 기관(CRO) 등으로 세분화됩니다. 2021년에는 다양한 연구 기관에서 에피제네틱스 검사의 효능에 대한 연구를 수행함에 따라 학술 및 연구 기관 부문이 시장을 지배할 것으로 예상됩니다.
- On the basis of distribution channel, the North America epigenetics diagnostic market is segmented into direct tender and retail sales. In 2021, direct tender segment is expected to dominate the market due to escalation in marketing activities and improved customer services in North American region.
North America Epigenetics Diagnostic Market Country Level Analysis
North America epigenetics diagnostic market is analysed, and market size information is provided by country, product, technology, type of therapy, application, end user, and distribution channel.
The countries covered in the North America epigenetics diagnostic market report are U.S., Canada and Mexico.
The U.S. is expected to grow in North America epigenetics diagnostic market, due to the increasing demand for epigenetics diagnosis because of high prevalence of chronic diseases and increasing healthcare infrastructure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
The Presence of Advanced Technology and Strategic Initiatives Taken by Players are Creating New Opportunities in the North America Epigenetics Diagnostic Market
North America epigenetics diagnostic market also provides you with detailed market analysis for every country's growth in a particular industry with products sales, the impact of advancement in the market, and changes in regulatory scenarios with their support for the epigenetics diagnostic market. The data is available for the historic period 2010 to 2019.
Competitive Landscape and North America Epigenetics Diagnostic Market Share Analysis
North America epigenetics diagnostic market competitive landscape provide details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to epigenetics diagnostic market.
후생유전학 진단을 제공하는 주요 기업으로는 Zymo Research Corporation, PerkinElmer Inc., Diagenode, F. Hoffman-La Roche Ltd, EPICYPHER, Promega Corporation, QIAGEN, Pacific Biosciences of California, Inc., Epigenomics AG, Mnemo, Reaction Biology, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Merck KGaA, Illumina, Inc., ACTIVEMOTIF, New England Biolabs, Thermo Fisher Scientific, Inc., EpiGentek Group Inc., Enzo Life Sciences, Inc., Epizyme, Inc., GlaxoSmithKline plc., Eclipse BioInnovations, MDxHealth, Abcam plc, Salarius Pharmaceuticals, Inc., Datar Cancer Genetics, Bluestar Genomics Inc. 등이 있습니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁사에 대한 경쟁 분석을 별도로 제공합니다.
시장 참여자들의 전략적 이니셔티브와 유전학 진단을 위한 새로운 기술 발전은 다양한 치료법의 격차를 메우고 있습니다.
예를 들어,
- 2021년 5월, Abcam Plc.는 항저우와 상하이에 새로운 맞춤형 시설을 오픈하면서 중국에서의 입지를 확장한다고 발표했습니다. 이 확장은 회사의 매출 성장을 확대할 것으로 예상됩니다.
시장 참여자의 협력, 합작투자 및 기타 전략은 유전학 진단 시장에서 회사의 시장을 강화하고 있으며, 이를 통해 조직이 유전학 진단 시장에 대한 제공 사항을 개선하는 데에도 도움이 됩니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S 5 FORCES
5 REGULATIONS: NORTH AMERICA EPIGENETICS DIAGNOSITC MARKET
5.1 UNITED STATES
5.1.1 ROLE OF FDA
5.1.2 ROLE OF CDC AND HCFA
5.2 EUROPEAN UNION
5.3 FRANCE
5.4 AUSTRALIA
5.5 SOUTH KOREA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF CANCER
6.1.2 INCREASE IN NORTH AMERICA GERIATRIC POPULATION
6.1.3 RISE IN RESEARCH & DEVELOPMENT (R&D) ACTIVITIES IN THE FIELD OF EPIGENETICS
6.1.4 PRESENCE OF ADVANCED TECHNOLOGIES TO IMPROVE DIAGNOSTIC EFFICIENCY
6.1.5 IMPROVING HEALTHCARE FACILITIES
6.2 RESTRAINTS
6.2.1 INADEQUACY IN IDENTIFICATION AND VALIDATION OF BIOMARKERS
6.2.2 HIGH COST OF EPIGENETICS DIAGNOSTIC EQUIPMENT
6.3 OPPORTUNITIES
6.3.1 WIDE RANGE OF APPLICATION
6.3.2 PROMOTER METHYLATION IN DIFFERENT TYPES OF CANCER
6.3.3 EMERGING MARKETS
6.3.4 INCREASING HEALTHCARE EXPENDITURE
6.3.5 RISING PER CAPITA INCOME
6.4 CHALLENGES
6.4.1 ESCALATING PRODUCT RECALL
6.4.2 SHORTAGE OF SKILLED PERSONNEL
6.4.3 EMERGENCE OF COVID-19
6.4.4 LACK OF ACCESSIBILITY
7 COVID-19 IMPACT ON NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY
7.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID 19
7.5 CONCLUSION:
8 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 REAGENTS
8.2.1 ANTIBODIES
8.2.2 BUFFERS
8.2.3 HISTONES
8.2.4 MAGNETIC BEADS
8.2.5 PRIMERS
8.2.6 OTHERS
8.3 KITS
8.3.1 CHIP SEQUENCING KIT
8.3.2 WHOLE GENOMIC AMPLIFICATION KIT
8.3.3 BISULFITE CONVERSION KIT
8.3.4 5-HMC & 5-MC ANALYSIS KITS
8.3.5 RNA SEQUENCING KIT
8.3.6 OTHERS
8.4 INSTRUMENTS & CONSUMABLES
8.4.1 NEXT-GENERATION SEQUENCERS
8.4.2 QPCR
8.4.3 MASS SPECTROMETERS
8.4.4 SONICATORS
8.4.5 OTHERS
8.5 BIOINFORMATICS TOOLS
8.6 ENZYMES
8.6.1 DNA-MODIFYING ENZYMES
8.6.2 PROTEIN-MODIFYING ENZYMES
8.6.3 RNA-MODIFYING ENZYMES
8.6.4 OTHERS
9 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 DNA METHYLATION
9.2.1 REAGENTS
9.2.2 KITS
9.2.3 INSTRUMENTS & CONSUMABLES
9.2.4 ENZYMES
9.3 HISTONE METHYLATION
9.3.1 REAGENTS
9.3.2 KITS
9.3.3 INSTRUMENTS & CONSUMABLES
9.3.4 ENZYMES
9.4 HISTONE ACETYLATION
9.4.1 REAGENTS
9.4.2 KITS
9.4.3 INSTRUMENTS & CONSUMABLES
9.4.4 ENZYMES
9.5 LARGE NON-CODING RNA
9.5.1 REAGENTS
9.5.2 KITS
9.5.3 INSTRUMENTS & CONSUMABLES
9.5.4 ENZYMES
9.6 MICRORNA MODIFICATION
9.6.1 REAGENTS
9.6.2 KITS
9.6.3 INSTRUMENTS & CONSUMABLES
9.6.4 ENZYMES
9.7 CHROMATIN STRUCTURES
9.7.1 REAGENTS
9.7.2 KITS
9.7.3 INSTRUMENTS & CONSUMABLES
9.7.4 ENZYMES
10 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY
10.1 OVERVIEW
10.2 HISTONE DEACETYLASE (HDAC) INHIBITORS
10.3 DNA METHYLTRANSFERASE (DNMT) INHIBITORS
10.4 OTHERS
11 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 ONCOLOGY
11.2.1 SOLID TUMORS
11.2.2 LIQUID TUMORS
11.3 CARDIOVASCULAR DISEASES
11.4 METABOLIC DISEASES
11.4.1 METABOLIC SYNDROME
11.4.2 TYPE 2 DIABETES (T2D)
11.4.3 OTHERS
11.5 IMMUNOLOGY
11.6 INFLAMMATORY DISEASES
11.7 INFECTIOUS DISEASES
11.8 OTHERS
12 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY END USER
12.1 OVERVIEW
12.2 ACADEMIC AND RESEARCH INSTITUTES
12.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
12.4 CONTRACT RESEARCH ORGANIZATIONS (CROS)
12.5 OTHERS
13 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
14 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY REGION
14.1 NORTH AMERICA
14.1.1 U.S.
14.1.2 CANADA
14.1.3 MEXICO
15 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 ILLUMINA, INC.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 THERMO FISHER SCIENTIFIC INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 MERCK KGAA
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 BIO-RAD LABORATORIES, INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 F. HOFFMANN-LA ROCHE LTD
17.5.1 COMPANY SNAPSHOT
17.5.2 RECENT FINANCIALS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.6 AGILENT TECHNOLOGIES, INC.
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 PERKINELMER INC
17.7.1 COMPANY SNAPSHOT
17.7.2 RECENT FINANCIALS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENTS
17.8 QIAGEN
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENTS
17.9 ABCAM PLC.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENTS
17.1 ACTIVEMOTIF
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 BLUESTAR GENOMICS INC.
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENTS
17.12 CAMBRIDGE EPIGENETIX (CEGX)
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.13 DATAR CANCER GENETICS
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENTS
17.14 DIAGENODE
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENTS
17.15 ECLIPSE BIOINNOVATIONS
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 ENZO LIFE SCIENCES, INC.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 EPICYPHER
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENTS
17.18 EPIGENOMICS AG
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENT
17.19 EPIGENTEK GROUP INC.
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENTS
17.2 EPIZYME, INC.
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENTS
17.21 GLAXOSMITHKLINE PLC.
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENTS
17.22 MDXHEALTH
17.22.1 COMPANY SNAPSHOT
17.22.2 PRODUCT PORTFOLIO
17.22.3 RECENT DEVELOPMENT
17.23 MNEMO
17.23.1 COMPANY SNAPSHOT
17.23.2 PRODUCT PORTFOLIO
17.23.3 RECENT DEVELOPMENT
17.24 NEW ENGLAND BIOLABS
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENTS
17.25 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
17.25.1 COMPANY SNAPSHOT
17.25.2 RECENT FINANCIALS
17.25.3 PRODUCT PORTFOLIO
17.25.4 RECENT DEVELOPMENTS
17.26 PROMEGA CORPORATION
17.26.1 COMPANY SNAPSHOT
17.26.2 PRODUCT PORTFOLIO
17.26.3 RECENT DEVELOPMENT
17.27 REACTION BIOLOGY
17.27.1 COMPANY SNAPSHOT
17.27.2 PRODUCT PORTFOLIO
17.27.3 RECENT DEVELOPMENTS
17.28 SALARIUS PHARMACEUTICALS, INC.
17.28.1 COMPANY SNAPSHOT
17.28.2 RECENT FINANCIALS
17.28.3 PRODUCT PORTFOLIO
17.28.4 RECENT DEVELOPMENTS
17.29 ZYMO RESEARCH CORPORATION
17.29.1 COMPANY SNAPSHOT
17.29.2 PRODUCT PORTFOLIO
17.29.3 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
표 목록
TABLE 1 HEALTH CARE FACILITIES
TABLE 2 PER CAPITA AMOUNTS: UNITED STATES (1960–2017 YEARS)
TABLE 3 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA REAGENTS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA REAGENTS IN EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA KITS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA KITS IN EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA BIOINFORMATICS TOOLS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA ENZYMES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA ENZYMES IN EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA DNA METHYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA DNA METHYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA HISTONE METHYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA HISTONE METHYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA HISTONE DEACETYLASE (HDAC) INHIBITORS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA DNA METHYLTRANSFERASE (DNMT) INHIBITORS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA OTHERS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA ONCOLOGY IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA ONCOLOGY IN EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA CARDIOVASCULAR DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA METABOLIC DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 NORTH AMERICA METABOLIC DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA IMMUNOLOGY IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 NORTH AMERICA INFLAMMATORY DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 NORTH AMERICA INFECTIOUS DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA OTHERS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 41 NORTH AMERICA ACADEMIC AND RESEARCH INSTITUTES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 NORTH AMERICA PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 NORTH AMERICA CONTRACT RESEARCH ORGANIZATIONS (CROS) IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 NORTH AMERICA OTHERS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 46 NORTH AMERICA DIRECT TENDER IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 NORTH AMERICA RETAIL SALES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 49 NORTH AMERICA EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 50 NORTH AMERICA REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 52 NORTH AMERICA INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 53 NORTH AMERICA ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 54 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 56 NORTH AMERICA HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 57 NORTH AMERICA HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 58 NORTH AMERICA LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 59 NORTH AMERICA MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 60 NORTH AMERICA CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 61 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 62 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 63 NORTH AMERICA ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 64 NORTH AMERICA METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 65 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 66 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 67 U.S. EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 68 U.S. REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 69 U.S. KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 70 U.S. INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 71 U.S. ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 72 U.S. EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 73 U.S. DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 74 U.S. HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 75 U.S. HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 76 U.S. LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 77 U.S. MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 78 U.S. CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 79 U.S. EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 80 U.S. EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 81 U.S. ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 82 U.S. METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 83 U.S. EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 84 U.S. EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 85 CANADA EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 86 CANADA REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 87 CANADA KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 88 CANADA INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 89 CANADA ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 90 CANADA EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 91 CANADA DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 92 CANADA HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 93 CANADA HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 94 CANADA LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 95 CANADA MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 96 CANADA CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 97 CANADA EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 98 CANADA EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 99 CANADA ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 100 CANADA METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 101 CANADA EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 102 CANADA EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 103 MEXICO EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 104 MEXICO REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 105 MEXICO KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 106 MEXICO INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 107 MEXICO ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 108 MEXICO EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 109 MEXICO DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 110 MEXICO HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 111 MEXICO HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 112 MEXICO LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 113 MEXICO MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 114 MEXICO CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 115 MEXICO EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 116 MEXICO EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 117 MEXICO ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 118 MEXICO METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 119 MEXICO EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 120 MEXICO EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
그림 목록
FIGURE 1 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF CANCER IS EXPECTED TO DRIVE THE NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 REAGENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET
FIGURE 15 EPIGENETIC REGULATION IN CANCER
FIGURE 16 PREVALENCE OF CANCER WORLDWIDE
FIGURE 17 ESTIMATED AGE-STANDARDIZED INCIDENCE RATES WORLDWIDE
FIGURE 18 NORTH AMERICA AGING POPULATION (IN MILLIONS)
FIGURE 19 GERIATRIC POPULATION WORLWIDE
FIGURE 20 NCI FUNDING FOR CANCER RESEARCH
FIGURE 21 EPIGENETIC IVD TESTS
FIGURE 22 THREE NEXT GENERATION SEQUENCING PLATFORMS
FIGURE 23 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT, 2020
FIGURE 24 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT, 2021-2028 (USD MILLION)
FIGURE 25 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT, CAGR (2021-2028)
FIGURE 26 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 27 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY TECHNOLOGY, 2020
FIGURE 28 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY TECHNOLOGY, 2021-2028 (USD MILLION)
FIGURE 29 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY TECHNOLOGY, CAGR (2021-2028)
FIGURE 30 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 31 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY TYPE OF THERAPY, 2020
FIGURE 32 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY TYPE OF THERAPY, 2021-2028 (USD MILLION)
FIGURE 33 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY TYPE OF THERAPY, CAGR (2021-2028)
FIGURE 34 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY TYPE OF THERAPY, LIFELINE CURVE
FIGURE 35 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY APPLICATION, 2020
FIGURE 36 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY APPLICATION, 2021-2028 (USD MILLION)
FIGURE 37 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 38 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 39 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY END USER, 2020
FIGURE 40 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 41 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY END USER, CAGR (2021-2028)
FIGURE 42 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 44 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 45 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 46 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: SNAPSHOT (2020)
FIGURE 48 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY COUNTRY (2020)
FIGURE 49 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2028)
FIGURE 50 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY COUNTRY (2020 & 2028)
FIGURE 51 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT (2021-2028)
FIGURE 52 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: COMPANY SHARE 2020 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
